<p>(<b>A</b>) The cumulative distribution of the somatic mutations identified on the targeted exons of the four patients’ primary tumors (P) as well as tumor models (N: Neurospheres, C: Cell culture, X: Xenograft) is reported as a function of their class and predicted protein changes. The mutations were identified after excluding mouse reads from patients’ SK00102 and SK00072 data. (<b>B</b>) A statistical comparison of the somatic mutations called between primary and model identifies shared mutations at constant mutant allele frequencies (black), shared mutations with changing mutant allele frequency (red) as well mutations specific to the primary (green) or the tumor model (blue). (<b>C–F</b>) Mutant Allele frequency differences between t...
Patient-derived xenograft (PDX) models are useful tools for tumor biology research and testing the e...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...
<p>(<b>A</b>) The cumulative distribution of the somatic mutations identified on the targeted exons ...
<p>Comparison of shared and exclusive variants in serum and tumor tissue pairs compared to the COSMI...
a. The graphical summary of somatic mutations of the 4 genes in molecular subtypes. All of the 190 t...
Human cancer somatic mutations arise from a variety of biological processes. Different processes pro...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
<p>Ten CSMD1 somatic mutation were found in Tumor 517. However, these particular mutations occur at ...
<p>(A) Recall (grey) and precision (tan) of detected somatic mutations. Recall = number of somatic m...
<p>Proportion of somatic SNVs by class (C->A, C->G, C->T, T->A, T->C and T-G) in the primary, metast...
Statistical analysis of pathogenicity of somatic mutations in cancer Recent large-scale sequencing s...
The development of new DNA sequencing techniques have made it possible to generate high-resolution g...
Patient-derived xenograft (PDX) models are useful tools for tumor biology research and testing the e...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...
<p>(<b>A</b>) The cumulative distribution of the somatic mutations identified on the targeted exons ...
<p>Comparison of shared and exclusive variants in serum and tumor tissue pairs compared to the COSMI...
a. The graphical summary of somatic mutations of the 4 genes in molecular subtypes. All of the 190 t...
Human cancer somatic mutations arise from a variety of biological processes. Different processes pro...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
Mutations associated with tumorigenesis may either arise somatically or can be inherited through the...
<p>Ten CSMD1 somatic mutation were found in Tumor 517. However, these particular mutations occur at ...
<p>(A) Recall (grey) and precision (tan) of detected somatic mutations. Recall = number of somatic m...
<p>Proportion of somatic SNVs by class (C->A, C->G, C->T, T->A, T->C and T-G) in the primary, metast...
Statistical analysis of pathogenicity of somatic mutations in cancer Recent large-scale sequencing s...
The development of new DNA sequencing techniques have made it possible to generate high-resolution g...
Patient-derived xenograft (PDX) models are useful tools for tumor biology research and testing the e...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...
Background: An increasing number of anti-cancer therapeutic agents target specific mutant proteins t...